ALNYLAM PHARMACEUTICALS, INC. Restricted Cash and Cash Equivalents, Noncurrent
ALNYLAM PHARMACEUTICALS, INC. (ALNY) had Restricted Cash and Cash Equivalents, Noncurrent of $2.14 million as of 2018-09-30, per its 10-Q filed 2018-11-07.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:RestrictedCashAndCashEquivalentsNoncurrent · last filed 2018-11-07
- 2018-09-30: Restricted Cash and Cash Equivalents, Noncurrent $2.14M.
- 2018-06-30: Restricted Cash and Cash Equivalents, Noncurrent $1.93M.
- 2018-03-31: Restricted Cash and Cash Equivalents, Noncurrent $1.73M.
- 2017-09-30: Restricted Cash and Cash Equivalents, Noncurrent $1.47M.
| Period end | Restricted Cash and Cash Equivalents, Noncurrent |
|---|---|
| 2018-09-30 | $2.14M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $1.93M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $1.73M 10-Q · filed 2018-05-04 |
| 2017-09-30 | $1.47M 10-Q · filed 2018-11-07 |
| 2017-06-30 | $1.47M 10-Q · filed 2018-08-02 |
| 2017-03-31 | $1.47M 10-Q · filed 2018-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |